A new study has found that combining the drug pioglitazone with exenatide, in the form of AstraZeneca’s bydureon therapy, provides better blood sugar control in type 2 diabetes than insulin alone and helps promote weight loss.
A new study has found that combining the drug pioglitazone with exenatide, in the form of AstraZeneca’s bydureon therapy, provides better blood sugar control in type 2 diabetes than insulin alone and helps promote weight loss.